Capstone Investment Advisors LLC Purchases New Stake in Biohaven Ltd. (NYSE:BHVN)

Capstone Investment Advisors LLC acquired a new position in shares of Biohaven Ltd. (NYSE:BHVNFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,486 shares of the company’s stock, valued at approximately $235,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Redmile Group LLC acquired a new stake in shares of Biohaven during the third quarter worth approximately $13,497,000. First Turn Management LLC acquired a new stake in shares of Biohaven during the 4th quarter valued at $20,429,000. Stifel Financial Corp grew its holdings in shares of Biohaven by 7.9% during the 4th quarter. Stifel Financial Corp now owns 6,225,811 shares of the company’s stock valued at $266,465,000 after acquiring an additional 456,062 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of Biohaven in the fourth quarter worth $11,402,000. Finally, Armistice Capital LLC increased its stake in shares of Biohaven by 13.1% in the third quarter. Armistice Capital LLC now owns 2,036,000 shares of the company’s stock worth $52,956,000 after acquiring an additional 236,000 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Price Performance

BHVN stock opened at $35.10 on Monday. Biohaven Ltd. has a 12 month low of $15.56 and a 12 month high of $62.21. The firm has a 50 day moving average of $43.17 and a two-hundred day moving average of $43.81.

Biohaven (NYSE:BHVNGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($2.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.50) by ($0.70). Research analysts anticipate that Biohaven Ltd. will post -7.16 EPS for the current year.

Insider Buying and Selling

In other news, CEO Vlad Coric acquired 121,951 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average cost of $41.00 per share, with a total value of $4,999,991.00. Following the acquisition, the chief executive officer now owns 1,788,417 shares in the company, valued at $73,325,097. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Gregory Bailey purchased 25,503 shares of Biohaven stock in a transaction on Wednesday, April 24th. The stock was purchased at an average cost of $39.18 per share, with a total value of $999,207.54. Following the acquisition, the director now directly owns 1,600,071 shares in the company, valued at $62,690,781.78. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Vlad Coric purchased 121,951 shares of Biohaven stock in a transaction on Monday, April 22nd. The stock was bought at an average cost of $41.00 per share, with a total value of $4,999,991.00. Following the completion of the acquisition, the chief executive officer now owns 1,788,417 shares in the company, valued at $73,325,097. The disclosure for this purchase can be found here. In the last three months, insiders bought 252,734 shares of company stock valued at $9,997,764. Company insiders own 16.00% of the company’s stock.

Analyst Ratings Changes

BHVN has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $59.00 price objective on shares of Biohaven in a research report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a research note on Tuesday, April 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research note on Thursday. TD Cowen boosted their target price on shares of Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Finally, UBS Group boosted their target price on shares of Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $51.63.

Read Our Latest Analysis on Biohaven

Biohaven Company Profile

(Free Report)

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

See Also

Institutional Ownership by Quarter for Biohaven (NYSE:BHVN)

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.